001     141513
005     20240321220952.0
024 7 _ |a 10.3233/JPD-191672
|2 doi
024 7 _ |a pmid:31381528
|2 pmid
024 7 _ |a 1877-7171
|2 ISSN
024 7 _ |a 1877-718X
|2 ISSN
024 7 _ |a altmetric:64772597
|2 altmetric
037 _ _ |a DZNE-2020-07837
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Löhle, Matthias
|0 P:(DE-2719)2813524
|b 0
|e First author
|u dzne
245 _ _ |a Putaminal Dopamine Turnover in de novo Parkinson's Disease Predicts Later Neuropsychiatric Fluctuations but Not Other Major Health Outcomes.
260 _ _ |a Amsterdam
|c 2019
|b IOS Press
264 _ 1 |3 print
|2 Crossref
|b IOS Press
|c 2019-10-11
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1708347608_1851
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a To investigate the predictive value of striatal dopamine turnover in patients with de novo Parkinson's disease (PD) for later occurrence of major non-motor health outcomes.This retrospective, observer-blinded cohort study followed up 29 patients with de novo PD for a median of 10.7 years, who completed 18Fluorodopa PET imaging to measure striatal effective distribution volume ratio (EDVR, inverse of dopamine turnover) prior to antiparkinsonian treatment. Outcomes were assessed with a battery of non-motor, health-related quality-of-life and non-motor fluctuation (WOQ-19) measures and survival.During follow-up, 52% of patients developed wearing-off, 43% neuropsychiatric fluctuations, 35% sensory fluctuations, 32% dementia, 46% depression, 30% psychosis, and PD-related mortality was 26%. Patients with wearing-off and neuropsychiatric fluctuations showed significantly lower baseline EDVR (higher dopamine turnover) in the putamen but not in the caudate nucleus than those without these fluctuations. Consistently, baseline EDVR in the putamen predicted development of wearing-off and neuropsychiatric fluctuations with a lower risk with higher EDVR (lower dopamine turnover), whereas EDVR in caudate nucleus did not correlate with these fluctuations. No relationships were observed between baseline PET measures and the presence of other major health outcomes including survival.Lower putaminal dopamine turnover in de novo PD is associated with reduced risk for later neuropsychiatric fluctuations comprising a disease-intrinsic predisposing factor for their development, similar as reported for levodopa-induced motor complications. Striatal (putaminal/caudate) dopamine turnover is not predictive for other long-term major health outcomes. These results should be treated as hypothesis generating and require confirmation.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Caudate Nucleus: diagnostic imaging
|2 MeSH
650 _ 2 |a Caudate Nucleus: metabolism
|2 MeSH
650 _ 2 |a Dopamine: metabolism
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Fluorodeoxyglucose F18
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Neuropsychological Tests
|2 MeSH
650 _ 2 |a Parkinson Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Parkinson Disease: metabolism
|2 MeSH
650 _ 2 |a Parkinson Disease: psychology
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a Putamen: diagnostic imaging
|2 MeSH
650 _ 2 |a Putamen: metabolism
|2 MeSH
650 _ 2 |a Quality of Life
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
700 1 _ |a Hermann, Wiebke
|0 P:(DE-2719)2814194
|b 1
|u dzne
700 1 _ |a Hausbrand, Denise
|b 2
700 1 _ |a Wolz, Martin
|b 3
700 1 _ |a Mende, Julia
|b 4
700 1 _ |a Beuthien-Baumann, Bettina
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Oehme, Liane
|b 6
700 1 _ |a van den Hoff, Jörg
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Kotzerke, Jörg
|b 8
700 1 _ |a Reichmann, Heinz
|b 9
700 1 _ |a Hermann, Andreas
|0 P:(DE-2719)2811732
|b 10
|u dzne
700 1 _ |a Storch, Alexander
|0 P:(DE-2719)9000306
|b 11
|e Last author
|u dzne
773 1 8 |a 10.3233/jpd-191672
|b : IOS Press, 2019-10-11
|n 4
|p 693-704
|3 journal-article
|2 Crossref
|t Journal of Parkinson's Disease
|v 9
|y 2019
|x 1877-7171
773 _ _ |a 10.3233/JPD-191672
|g Vol. 9, no. 4, p. 693 - 704
|0 PERI:(DE-600)2599550-9
|n 4
|q 9:4<693 - 704
|p 693-704
|t Journal of Parkinson's Disease
|v 9
|y 2019
|x 1877-7171
856 4 _ |u https://pub.dzne.de/record/141513/files/DZNE-2020-07837_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/141513/files/DZNE-2020-07837_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:141513
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2813524
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2814194
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2811732
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9000306
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2019
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J PARKINSON DIS : 2021
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J PARKINSON DIS : 2021
|d 2022-11-25
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
920 1 _ |0 I:(DE-2719)5000014
|k AG Storch
|l Non-Motor Symptoms in Parkinson's disease
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)5000014
980 _ _ |a UNRESTRICTED
999 C 5 |9 -- missing cx lookup --
|a 10.1038/nrneurol.2012.126
|2 Crossref
|o 10.1038/nrneurol.2012.126
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.25157
|2 Crossref
|o 10.1002/mds.25157
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.parkreldis.2018.05.008
|2 Crossref
|o 10.1016/j.parkreldis.2018.05.008
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.parkreldis.2017.06.013
|2 Crossref
|o 10.1016/j.parkreldis.2017.06.013
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.parkreldis.2014.05.010
|2 Crossref
|o 10.1016/j.parkreldis.2014.05.010
999 C 5 |9 -- missing cx lookup --
|a 10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4
|2 Crossref
|o 10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4
999 C 5 |9 -- missing cx lookup --
|a 10.1093/brain/awl028
|2 Crossref
|o 10.1093/brain/awl028
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0b013e3182918c2d
|2 Crossref
|o 10.1212/WNL.0b013e3182918c2d
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.27466
|2 Crossref
|o 10.1002/mds.27466
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0000000000002286
|2 Crossref
|o 10.1212/WNL.0000000000002286
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s00702-006-0554-y
|2 Crossref
|o 10.1007/s00702-006-0554-y
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.parkreldis.2014.11.002
|2 Crossref
|o 10.1016/j.parkreldis.2014.11.002
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.21944
|2 Crossref
|o 10.1002/mds.21944
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.23875
|2 Crossref
|o 10.1002/mds.23875
999 C 5 |y 2018
|2 Crossref
|o Mantese 2018
999 C 5 |y 1987
|2 Crossref
|t Recent developments in Parkinson’s disease.
|o Fahn Recent developments in Parkinson’s disease. 1987
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s00415-014-7299-6
|2 Crossref
|o 10.1007/s00415-014-7299-6
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.21333
|2 Crossref
|o 10.1002/mds.21333
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.20844
|2 Crossref
|o 10.1002/mds.20844
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.10656
|2 Crossref
|o 10.1002/mds.10656
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0b013e3181c34b47
|2 Crossref
|o 10.1212/WNL.0b013e3181c34b47
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.parkreldis.2012.08.004
|2 Crossref
|o 10.1016/j.parkreldis.2012.08.004
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.23429
|2 Crossref
|o 10.1002/mds.23429
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s00259-011-1819-8
|2 Crossref
|o 10.1007/s00259-011-1819-8
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.25364
|2 Crossref
|o 10.1002/mds.25364
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.25319
|2 Crossref
|o 10.1002/mds.25319
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0000000000000385
|2 Crossref
|o 10.1212/WNL.0000000000000385
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.26731
|2 Crossref
|o 10.1002/mds.26731
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0b013e318285c0ed
|2 Crossref
|o 10.1212/WNL.0b013e318285c0ed
999 C 5 |9 -- missing cx lookup --
|a 10.1136/jnnp-2017-316213
|2 Crossref
|o 10.1136/jnnp-2017-316213
999 C 5 |9 -- missing cx lookup --
|a 10.1002/ana.21204
|2 Crossref
|o 10.1002/ana.21204
999 C 5 |9 -- missing cx lookup --
|a 10.1136/jnnp.49.10.1182
|2 Crossref
|o 10.1136/jnnp.49.10.1182
999 C 5 |9 -- missing cx lookup --
|a 10.3233/JPD-160996
|2 Crossref
|o 10.3233/JPD-160996
999 C 5 |9 -- missing cx lookup --
|a 10.1093/brain/119.6.2121
|2 Crossref
|o 10.1093/brain/119.6.2121
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.27190
|2 Crossref
|o 10.1002/mds.27190
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S1474-4422(16)30328-3
|2 Crossref
|o 10.1016/S1474-4422(16)30328-3
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0000000000003810
|2 Crossref
|o 10.1212/WNL.0000000000003810
999 C 5 |9 -- missing cx lookup --
|a 10.1159/000341998
|2 Crossref
|o 10.1159/000341998


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21